Summary of Product Characteristics (SmPC) - Cocois (Coconut oil Compound ointment)
1 NAME OF THE MEDICINAL PRODUCT
Cocois (Coconut Oil Compound Ointment).
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
| Active ingredients | % w/w |
| Coal Tar Solution BP | 12.0 |
| Precipitated Sulphur Ph.Eur | 4.0 |
| Salicylic Acid Ph.Eur | 2.0 |
Excipient(s) with known effect: Contains cetostearyl alcohol 11.00% w/w
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Ointment for topical application.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Cocois has mild, antipruritic, antiseptic and keratolytic properties. It is indicated in the treatment of scaly skin disorders of the scalp such as psoriasis, eczema, seborrhoeic dermatitis and dandruff.
4.2 Posology and method of administration
Adults, children over 12 years and the elderly
Mild dandruff
To be used intermittently as an adjunctive treatment to be applied approximately once a week.
Psoriasis, eczema, seborrhoeic dermatitis and severe dandruff
To be used daily for three to seven days until improvement has been achieved. Intermittent repeated applications may be necessary to maintain improvement.
In all cases, the affected area should be treated and shampooed off using warm water approximately one hour later.
Children 6-12 years
To be used under medical supervision only.
Children under 6 years
Not recommended.
4.3 Contraindications
Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1
The product is contraindicated in patients known to be sensitive to any of the ingredients including sulphur and salicylates, in the presence of acute local infections, or acute pustular psoriasis.
Third trimester of pregnancy.
4.4 Special warnings and precautions for use
Do not use on inflamed or broken skin. Avoid contact with mouth, mucous membranes and eyes and wash hands immediately after use. Discontinue use if irritation develops.
If symptoms persist after four weeks, a doctor should be consulted.
Cocois may stain fabrics and jewellery.
Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
4.5 Interaction with other medicinal products and other forms of interaction
None
4.6 Fertility, pregnancy and lactation
If possible Cocois should not be used during pregnancy or lactation. However, inadvertent, accidental exposure is not cause for clinical intervention. Minimal systemic absorption of salicylic acid may occur after topical application. There are no data on the use of coal tar in pregnant or lactation women. It is unknown whether coal tar crosses the placenta or is excreted in breast milk. There is no sufficient clinical experience to establish the safety of sulphur in general during pregnancy and lactation. It is unknown whether sulphur crosses the placenta or is excreted in breast milk.
There are no or limited amount of data from the use of Cocois during pregnancy.
It is not known if the systemic Cocois exposure reached after topical administration can be harmful to an embryo/fetus. During the first and second trimester of pregnancy, Cocois should not be used unless clearly necessary. If used, the dose should be kept as low and duration of treatment as short as possible.
During the third trimester of pregnancy, systemic use of prostaglandin synthetase inhibitors may induce cardiopulmonary and renal toxicity in the fetus. At the end of the pregnancy prolonged bleeding time in both mother and child may occur, and labour can be delayed. Therefore, Cocois is contraindicated during the last trimester of pregnancy (see Section 4.3).
4.7 Effects on ability to drive and use machines
None
4.8 Undesirable effects
Coal tar may cause skin irritation, folliculitis and rarely photosensitivity.
Cocois may cause skin irritations, acne like eruptions, dermatitis, folliculitis, alopecia and rarely photosensitivity and hypersensitivity. Discolouration of skin and hair may also occur.
Bronchospasm has been reported very rarely in patients with either pre-existing asthma or a family history of hypersensitivity to salicylates.
Although carcinogenicity of coal tar has been demonstrated in animal studies, no studies demonstrating an increased risk of skin cancer with normal therapeutic use in humans have been reported. There is no unequivocal evidence to link the use of topically applied coal tar products with skin cancer.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme on the MHRA website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Overdose is extremely unlikely. Treat symptomatically, if necessary.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Coal Tar is antipuritic, keratoplastic and a weak antiseptic.
Salicylic acid has keratolytic properties. Sulphur is a keratolytic, with weak antiseptic and parasiticide properties. Combinations of coal tar, salicylic acid and sulphur are widely used in the treatment of hyperkeratotic and scaling skin conditions.
5.2 Pharmacokinetic properties
No data is available for the proposed formulation.
5.3 Preclinical safety data
None stated.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Coconut Oil
White Soft Paraffin
Cetostearyl Alcohol
Glycerol
Liquid Paraffin
Polyoxyethylene Glycerol Monostearate Hard Paraffin
6.2 Incompatibilities
Not applicable
6.3 Shelf life
40g pack size
2 years.
100g pack size
18 months.
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
Cocois is packed into internally lacquered, aluminium tubes (5g, 15g, 40g and 100g) fitted with a polyethylene cap.
6.6 Special precautions for disposal
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements
7 MARKETING AUTHORISATION HOLDER
RPH Pharmaceuticals AB
Box 603
101 32 Stockholm
Sweden
8 MARKETING AUTHORISATION NUMBER(S)
PL 36301/0022
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
Date of first authorisation: 9th June 1997
Date of renewal: 6th November 1998
10 DATE OF REVISION OF THE TEXT
16/12/2025